Alemtuzumab

Alemtuzumab (Campath(®), MabCampath(®), Genzyme) is an IgG1k anti-CD52 humanized monoclonal antibody (mAb) that was first licensed in March 2001 by FDA. EMEA granted its approval in July 2001 and Health Canada in November 2005. The initial indication was limited to B-CLL previously treated and resis...

Descripción completa

Detalles Bibliográficos
Autor principal: Tridente, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122495/
http://dx.doi.org/10.1007/978-88-470-5313-7_7
_version_ 1783515430225182720
author Tridente, Giuseppe
author_facet Tridente, Giuseppe
author_sort Tridente, Giuseppe
collection PubMed
description Alemtuzumab (Campath(®), MabCampath(®), Genzyme) is an IgG1k anti-CD52 humanized monoclonal antibody (mAb) that was first licensed in March 2001 by FDA. EMEA granted its approval in July 2001 and Health Canada in November 2005. The initial indication was limited to B-CLL previously treated and resistant to alkylating agents. Starting from 2007, alemtuzumab was approved also as first-line therapy of B-CLL. So far, it has been experienced in over 60 countries. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/978-88-470-5313-7_7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7122495
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-71224952020-04-06 Alemtuzumab Tridente, Giuseppe Adverse Events with Biomedicines Article Alemtuzumab (Campath(®), MabCampath(®), Genzyme) is an IgG1k anti-CD52 humanized monoclonal antibody (mAb) that was first licensed in March 2001 by FDA. EMEA granted its approval in July 2001 and Health Canada in November 2005. The initial indication was limited to B-CLL previously treated and resistant to alkylating agents. Starting from 2007, alemtuzumab was approved also as first-line therapy of B-CLL. So far, it has been experienced in over 60 countries. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/978-88-470-5313-7_7) contains supplementary material, which is available to authorized users. 2013-07-12 /pmc/articles/PMC7122495/ http://dx.doi.org/10.1007/978-88-470-5313-7_7 Text en © Springer-Verlag Italia 2014 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Tridente, Giuseppe
Alemtuzumab
title Alemtuzumab
title_full Alemtuzumab
title_fullStr Alemtuzumab
title_full_unstemmed Alemtuzumab
title_short Alemtuzumab
title_sort alemtuzumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122495/
http://dx.doi.org/10.1007/978-88-470-5313-7_7
work_keys_str_mv AT tridentegiuseppe alemtuzumab

Ejemplares similares